We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01492218
First Posted: December 14, 2011
Last Update Posted: February 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
December 12, 2011
December 14, 2011
February 28, 2017
March 15, 2004
August 30, 2004   (Final data collection date for primary outcome measure)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Same as current
Complete list of historical versions of study NCT01492218 on ClinicalTrials.gov Archive Site
  • Adverse events
  • Technical complaints of NovoLet® device
Same as current
Not Provided
Not Provided
 
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients diagnosed with type 1 or type 2 diabetes mellitus and are not presently using Mixtard® 30 NovoLet®
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
Drug: biphasic human insulin 30
Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
NovoLet®
Intervention: Drug: biphasic human insulin 30
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1330
August 30, 2004
August 30, 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diabetes mellitus (type 1 or type 2)
  • Patient not presently using Mixtard® 30 NovoLet®
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Philippines
 
 
NCT01492218
NOPEN3-1885
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR,1452) Novo Nordisk A/S
Novo Nordisk A/S
February 2017